Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Last accessed: April 2023. vi Hack SP, Spahn J, Chen M et al. IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab ...

Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] Draft guidance Technology appraisal guidance 25 February 2025 Tarlatamab for previously treated ...

Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Cox-734, Boston, MA 02114. E-mail: [email ...

Objective: To evaluate whether the combination of immune checkpoint inhibitor (ICI) with chemotherapy is more effective than ICI alone in the treatment of recurrent, locoregionally advanced, ...

7 Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China Objective Hepatocellular carcinoma (HCC) is heterogeneous, especially in multifocal tumours, ...

This initiative aims to enhance access to cancer treatment and support for patients across the country, addressing a critical gap in healthcare services. Listen to Story India is witnessing growing ...